Tesamorelin is a synthetic analogue of human GHRH comprising the complete 44 amino acid sequence with a trans-3-hexenoic acid modification at the N-terminus, providing resistance to enzymatic cleavage while preserving full GHRH receptor binding activity. Tesamorelin received FDA approval in 2010 (Egrifta) for a specific clinical indication.
GHRH Receptor Full Agonism Research
Research has examined tesamorelin's full 44 amino acid GHRH sequence advantage over shorter analogues such as sermorelin (29 aa), comparing their GHRH receptor binding affinities and potencies in pituitary cell models.
GH and IGF-1 Axis Research
Clinical and preclinical research has extensively examined tesamorelin's effects on GH pulse parameters, IGF-1 and IGFBP-3 concentrations, and downstream metabolic markers. The FDA approval process generated substantial clinical research data on its pharmacokinetics and GH stimulation profile.
Visceral Adipose Tissue Research
A key clinical research application of tesamorelin involves its effects on visceral adipose tissue as measured by CT imaging in clinical study populations, examining GH axis-mediated mechanisms of GHRH analogue influence on visceral fat depot metabolism.
• Falutz J et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.
